After two years of deliberations, the UK's National Institute for Health and Clinical Excellence agreed to an arrangement that will allow patients to receive the Lucentis treatment for age-related macular degeneration. For the first time, however, a drugmaker will foot part of the bill in situations where government funding is insufficient.
Here's the plan: The first 14 injections of th...
